Going beyond the median: Estimating survival times for patients with hormone receptor positive, metastatic breast cancer commencing endocrine therapy

被引：0
|
作者：
Parsonson, Andrew O.
Sarkar, Sunit
Brown, Lauren
Kiely, Belinda
Vasista, Anuradha
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P3-01-10
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-01-10
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Beyond the Median: Estimating survival times for patients starting endocrine therapy for oestrogen receptor positive metastatic breast cancer
    Parsonson, Andrew O.
    Sarkar, Sunit
    Brown, Lauren
    Kiely, Belinda E.
    Vasista, Anuradha
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 136 - 136
  • [2] Beyond the median: Estimating survival times for patients starting endocrine therapy for estrogen receptor-positive, metastatic breast cancer from recent randomized trials
    Parsonson, Andrew O.
    Sarkar, Sunit
    Brown, Lauren
    Low, Gary K. K.
    Kiely, Belinda E.
    Vasista, Anuradha
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2024, 20 (06) : 714 - 722
  • [3] Endocrine therapy combined with targeted therapy in hormone receptor-positive metastatic breast cancer
    Bian, Li
    Xu, Feng-Rui
    Jiang, Ze-Fei
    CHINESE MEDICAL JOURNAL, 2020, 133 (19) : 2338 - 2345
  • [4] Endocrine therapy combined with targeted therapy in hormone receptor-positive metastatic breast cancer
    Bian Li
    Xu Feng-Rui
    Jiang Ze-Fei
    中华医学杂志英文版, 2020, 133 (19) : 2338 - 2345
  • [5] Trends in endocrine therapy prescription and survival in patients with non-metastatic hormone receptor positive breast cancer treated with endocrine therapy: A population based-study
    Kamga, Ariane Mamguem
    Billa, Oumar
    Ladoire, Sylvain
    Poillot, Marie-Laure
    Jolimoy, Genevieve
    Roignot, Patrick
    Coutant, Charles
    Desmoulins, Isabelle
    Maynadie, Marc
    Dabakuyo-Yonli, Tienhan Sandrine
    BREAST, 2021, 59 : 79 - 86
  • [6] ESTIMATING AND COMMUNICATING SURVIVAL TIMES FOR PATIENTS WITH METASTATIC BREAST CANCER
    Kiely, Belinda E.
    BREAST, 2019, 48 : S21 - S22
  • [7] Improved survival supports primary endocrine therapy in patients with hormone receptor positive/ HER-2 negative metastatic breast cancer.
    Shenk, Robert
    Cao, Lifen
    Bliggenstorfer, Jonathan T.
    Martin, James Michael
    Miller, Megan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Beyond median overall survival: Estimating multiple survival scenarios in patients with metastatic esophagogastric cancer
    Pape, Marieke
    Kuijper, Steven
    Vissers, Pauline A. J.
    Creemers, Geert-Jan
    Van Laarhoven, Hanneke W. M.
    Verhoeven, Rob
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [9] RETRACTION: Challenges of combined everolimus/endocrine therapy in hormone receptor-positive metastatic breast cancer
    Porta, Camillo
    ONCOLOGY REVIEWS, 2014, 8 (01) : 6 - 6
  • [10] Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
    Anishka D’Souza
    Darcy Spicer
    Janice Lu
    Journal of Hematology & Oncology, 11
12345